It may have been “A Waltz with Taltz” but it is “Looking Bleak for Siliq”. Spherix Global Insights highlights responses from 100 dermatologists about the evolving treatment patterns for biologics and novel small molecules in psoriasis. Added emphasis is on the recent introduction of two new IL-17s, Lilly’s Taltz and Valeant’s Siliq, featuring promotional activity, uptake curves, barriers and more. The next quarterly wave will field in early June.

Click the button below to download highlights from this report.

RTD: Psoriasis Spotlight